https://www.selleckchem.com/products/AT7867.html
Median TSkR was 54 months (95%CI 45-65). Among patients who received adjuvant AIs median TSkR was 35 months (95%CI 25-54), while among patients who did not was 61 months (95%CI 50-8 (HR = 1.45 [95%CI 0.97-2.17], p =0.0644). After adjusting for TNM stage (AJCC 8th edition), adjuvant AIs treatment was significantly related to a shorter TSkR (HR = 1.60 [95%CI 1.06-2.42], p =0.0244). Adjuvant Tamoxifen, adjuvant AIs/Tamoxifen and no-treatment did not revealed to be associated to TSkR. In this cohort of EBC patients with bone recurrence, AI
Like
Comment
Share
